Authors presented by alberts and goldberg analysis by scott berry date posted june 21 2010
This presentation is the property of its rightful owner.
Sponsored Links
1 / 15

Authors: Presented by Alberts and Goldberg Analysis By Scott Berry Date posted: June 21 2010 PowerPoint PPT Presentation


  • 48 Views
  • Uploaded on
  • Presentation posted in: General

Phase III Clinical Trial of FOLFOX with or without Cetuximab in Resected Stage 3 Colon Cancer: Cooperative Group Trial N0147 (NCCTG*, CALGB, ECOG, NCIC, NSABP, SWOG). Authors: Presented by Alberts and Goldberg Analysis By Scott Berry Date posted: June 21 2010.

Download Presentation

Authors: Presented by Alberts and Goldberg Analysis By Scott Berry Date posted: June 21 2010

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Authors presented by alberts and goldberg analysis by scott berry date posted june 21 2010

Phase III Clinical Trial of FOLFOX with or without Cetuximab in Resected Stage 3 Colon Cancer:Cooperative Group Trial N0147(NCCTG*, CALGB, ECOG, NCIC, NSABP, SWOG)

Authors: Presented by Alberts and Goldberg

Analysis By Scott Berry

Date posted: June 21 2010


Authors presented by alberts and goldberg analysis by scott berry date posted june 21 2010

Thank you for downloading this update. Please feel free to use it for educational purposes.

Please acknowledge OncologyEducation.ca and Dr. Berry when using these slides.


Authors presented by alberts and goldberg analysis by scott berry date posted june 21 2010

Initial Study Design

N=2300

Primary Outcome: DFS

Treatment A:

mFOLFOX6 (12 cycles)

R

Treatment B:

mFOLFOX6 + Cetux (12 cycles)


Authors presented by alberts and goldberg analysis by scott berry date posted june 21 2010

Revised Study Design

KRAS WT ONLY

N=3768

Primary Outcome: DFS

Treatment A:

mFOLFOX6 (12 cycles)

R

Treatment B:

mFOLFOX6 + Cetux (12 cycles)


Trial closed early

Trial Closed Early

  • 1864 randomized to A (FOLFOX) or D (FOLFOX + cetuximab)

    • Trial halted on findings of planned interim analysis

    • 90% of planned accrual

  • Median follow-up 23 months


Authors presented by alberts and goldberg analysis by scott berry date posted june 21 2010

RESULTS : KRAS-WT


Authors presented by alberts and goldberg analysis by scott berry date posted june 21 2010

Gr 3/4 TOXICITY


Reasons for discontinuation

Reasons for Discontinuation


Conclusions

Conclusions

  • No benefit to adding cetuximab in patients with resected stage 3 K-ras WT expressing colon cancer

  • ? Explanation

    • Decreased tolerance with cetuximab

    • Differences in dose intensity

    • Interaction with age:

      • Worse outcomes in older patients receiving cetuximab

      • Lessened ability to complete therapy


Was adverse impact of cetuximab due to dosing issues

Was adverse impact of Cetuximab due to dosing issues?

In post-hoc analysis, attempted to identify ‘ideal’ patients

First 6 cycles with > 80% dose intensity for all drugs

Consider only patients aged < 70

If no benefit in these pts (young, > 80% dose rec’d), then adverse impact not likely due to reduced dosing


Was adverse impact of cetuximab due to dosing issues1

Was adverse impact of Cetuximab due to dosing issues?

Comparison based on dosing not protected by randomization, thus possibly confounded with other reasons for stopping treatment

Alternative

Use Time to Recurrence endpoint

Most sensitive

Least confounded


Dose intensity with 80 k ras wt

Dose Intensity (% with > 80%) K-ras WT

Cycle 6

Cycle 10


Authors presented by alberts and goldberg analysis by scott berry date posted june 21 2010

“Idealized” Patient Comparison: Time to Recurrence – K-Ras WT

All Patients

“Ideal” Patients


Was adverse impact of cetuximab due to dosing issues2

Was adverse impact of Cetuximab due to dosing issues?

GOLDBERG:

While they had lower drug exposure, we don’t believe that is the key reason based on the idealized patient analysis

We believe that the explanation is related to tumor biology


Authors presented by alberts and goldberg analysis by scott berry date posted june 21 2010

STUDY COMMENTARY

  • Adding Cetuximab to adjuvant FOLFOX for resected Stage III colon cancer patients does not improve outcome

  • Results do not appear to be explained by attendant increased toxicity / decreased dose intensity with combination

  • ? Tumour Biology


  • Login